- Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?June 25, 2019 | Brad Kahl, MD
Dr. Kahl studies the biologic underpinnings of a new entity that does not meet the classical definition of double-hit (DH) DLBCL but has gene expression signatures and clinical outcomes very similar to DH DLBCL.
- Popping the Bubble: Promising Results From a Phase I-II Lentiviral Gene Therapy Trial for X-SCIDJune 24, 2019 | Danielle E. Arnold, MD | David T. Teachey, MD
Drs. Arnold and Teachey review a phase I-II trial observing self-inactivating-lentiviral gene therapy in eight consecutive male infants newly diagnosed with X-linked severe combined immunodeficiency and without a matched sibling donor.
- Poorer Pain Control With Normal Saline Bolus in Children With Sickle Cell Acute Vaso-Occlusive PainJune 18, 2019 | Ifeyinwa (Ify) Osunkwo, MD, MPH
Dr. Osunkwo reviews a study that challenges the belief that normal saline boluses are the best option to treat acute vaso-occlusive pain in sickle cell disease.
- RNA Isoforms, Innate Immunity, and Leukemogenesis: IRAK4 As a Novel Therapeutic Target in MDS/AMLJune 13, 2019 | Charlotte Brierley, MD | Adam Mead, MD, PhD
Drs. Brierley and Mead discuss a study that identified a poor-prognosis subtype of MDS/AML defined by the accumulation of certain mRNA isoform changes in innate immune pathway genes.
- On the Road to a Better CAR: Identifying the Variables Associated With a Durable Response to CAR T-Cell Therapy in Relapsed/Refractory B-ALLJune 05, 2019 | Carol Fries, MD | Kristen M. O'Dwyer, MD
Dr. Fries and Dr. O'Dwyer discuss reported data on a cohort of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received lymphodepleting chemotherapy followed by an infusion of autologous T cells, and look at variables associated with durable CAR-T therapy response.
- Seeking Insight Into the AML Subpopulations and Microenvironment Through Single-cell RNA-SeqJune 03, 2019 | Sameer S. Khatri, MD | Annette S. Kim, MD, PhD
Dr. Khatri and Dr. Kim study the acute myeloid leukemia subpopulations and microenvironment using high-throughput single-cell RNA sequencing.
- XBP1s: Getting to the Roots of Multiple MyelomaJune 03, 2019 | Shuai Dong, PhD | Sabrin Tahri, MD | Irene M. Ghobrial, MD
Drs. Dong, Tahri, and Ghobrial discuss using the B cell-specific XBP-1 transgenic murine model to define a plasma cell progenitor cells population in multiple myeloma.
- PET-adapted Strategies in Advanced Stage Hodgkin Lymphoma: Big to Small, or Small to Big, or Does It Even Matter?May 22, 2019 | Caron A. Jacobson, MD
Dr. Jacobson reviews a study that looks at positron emission tomography (PET)-adapted strategies for the treatment of advanced-stage Hodgkin lymphoma.
- Piecing Together the Bone Marrow NicheMay 22, 2019 | Victoria Y. Ling, MBBS, FRACP, FRCPA | Steven Lane, MBBS, PhD, FRACP, FRCPA
Dr. Ling and Dr. Lane discuss a study that helps piece together the complex, three-dimensional, living jigsaw puzzle that is the bone marrow hematopoietic stem cell niche.
- Superficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause HarmMay 22, 2019 | Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC
Dr. Linkins provides recommendations for treating superficial thrombophlebitis including whether anticoagulants are appropriate based on the risk of progression into the deep venous system.